FAM111A Gene Kenny-Caffey Syndrome Type 2 Genetic Test
At DNA Labs UAE, we offer the FAM111A Gene Kenny-Caffey syndrome type 2 Genetic Test at a cost of AED 4400.0.
Test Details
The FAM111A gene is associated with Kenny-Caffey syndrome type 2, a rare genetic disorder characterized by skeletal abnormalities and developmental delay. Our NGS (Next Generation Sequencing) genetic testing method allows us to analyze multiple genes simultaneously.
In the context of Kenny-Caffey syndrome type 2, our NGS genetic testing can identify any mutations or variations in the FAM111A gene that may be responsible for the disorder. To conduct this test, we require a sample of the individual’s DNA, which can be obtained through a blood or saliva sample.
Using NGS technology, we sequence the DNA to identify any variations or mutations in the FAM111A gene. The results of the test can confirm a diagnosis of Kenny-Caffey syndrome type 2 and provide information about the specific genetic variant involved.
Our NGS genetic testing can help in providing a more accurate diagnosis, guiding treatment decisions, and informing genetic counseling for affected individuals and their families. Additionally, the results can contribute to research efforts aimed at better understanding the genetic basis of Kenny-Caffey syndrome type 2 and potentially developing targeted therapies in the future.
Test Components and Price
Test Name: FAM111A Gene Kenny-Caffey syndrome type 2 Genetic Test
Components: NGS Technology
Price: AED 4400.0
Sample Condition
We accept the following sample conditions for the FAM111A Gene Kenny-Caffey syndrome type 2 Genetic Test:
- Blood
- Extracted DNA
- One drop of blood on FTA Card
Report Delivery
The report for the FAM111A Gene Kenny-Caffey syndrome type 2 Genetic Test will be delivered within 3 to 4 weeks.
Test Type and Doctor
Test Type: Neurological Disorders
Doctor: Neurologist
Test Department
The FAM111A Gene Kenny-Caffey syndrome type 2 Genetic Test is conducted in our Genetics department.
Pre Test Information
Prior to the FAM111A Gene Kenny-Caffey syndrome type 2 NGS Genetic DNA Test, it is important to provide the clinical history of the patient. Additionally, a genetic counseling session will be conducted to draw a pedigree chart of family members affected with FAM111A Gene Kenny-Caffey syndrome type 2.
Test Name | FAM111A Gene Kenny-Caffey syndrome type 2 Genetic Test |
---|---|
Components | |
Price | 4400.0 AED |
Sample Condition | Blood or Extracted DNA or One drop Blood on FTA Card o |
Report Delivery | 3 to 4 Weeks |
Method | NGS Technology |
Test type | Neurological Disorders |
Doctor | Neurologist |
Test Department: | Genetics |
Pre Test Information | Clinical History of Patient who is going for FAM111A Gene Kenny-Caffey syndrome type 2 NGS Genetic DNA Test A Genetic Counselling session to draw a pedigree chart of family members affected with FAM111A Gene Kenny-Caffey syndrome type 2 |
Test Details |
The FAM111A gene is associated with Kenny-Caffey syndrome type 2, which is a rare genetic disorder characterized by skeletal abnormalities and developmental delay. NGS (Next Generation Sequencing) genetic testing is a type of genetic testing that uses advanced sequencing technology to analyze multiple genes simultaneously. In the context of Kenny-Caffey syndrome type 2, NGS genetic testing can be used to identify any mutations or variations in the FAM111A gene that may be responsible for the disorder. This type of genetic testing involves obtaining a sample of the individual’s DNA, usually through a blood or saliva sample. The DNA is then sequenced using NGS technology to identify any variations or mutations in the FAM111A gene. The results of the test can help confirm a diagnosis of Kenny-Caffey syndrome type 2 and provide information about the specific genetic variant involved. NGS genetic testing can be helpful in providing a more accurate diagnosis, guiding treatment decisions, and informing genetic counseling for affected individuals and their families. It can also contribute to research efforts aimed at better understanding the genetic basis of Kenny-Caffey syndrome type 2 and potentially developing targeted therapies in the future. |